Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 4/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7197622 | 0.80 | CES1 (0.47) | CES1SRCTSHRALDH1A1LMNA | |
| SCHEMBL135045 | 0.79 | CES1 (0.54) | CES1SRCNR4A2TSHRALDH1A1 | |
| SCHEMBL27863476 | 0.79 | CES1 (0.46) | CES1SRCGAALMNACES2 | |
| SCHEMBL11289136 | 0.79 | CES1 (0.53) | CES1SRCTSHRALDH1A1LMNA | |
| Methoxymethane SCHEMBL5530887 | 0.77 | CES1 (0.51) | CES1SRCNR4A2TSHRALDH1A1 | |
| SCHEMBL28289195 | 0.77 | SMN1; SMN2 (0.43) | ALDH1A1CYP2C19HDAC3HDAC4HDAC1 | |
| SCHEMBL11616478 | 0.76 | NR4A2 (0.52) | CES1SRCNR4A2TSHRALDH1A1 | |
| SCHEMBL7198657 | 0.74 | NR4A2 (0.50) | CES1SRCNR4A2TSHRALDH1A1 | |
| SCHEMBL7200997 | 0.73 | PLA2G2D (0.38) | NR4A2ALDH1A1GAACYP2C19POLB | |
| SCHEMBL28079483 | 0.72 | CES1 (0.59) | CES1SRCTSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610663-B2 | Antisense compound with targeting and RNA cleaving moieties, preferably an imidazole functionality conjugated to the targeting oligonucleotide via linkers | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020160972-A1 | Compositions and methods for modulating RNA | ISIS PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6358931-B1 | OLIGONUCLETIDE CONJUGATED TO IMIDAZOLE; INTERCALATION AND COORDINATION COMPOUNDS; MEDICAL DIAGNOSIS, GENE THERAPY; ANTISENSE AGENTS | ISIS PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
| EP-0656790-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1995-06-14 | — | — | EP | disclosed |
| WO-1993017717-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160972-A1 | Compositions and methods for modulating RNA | RNGTT, NSUN3, NSUN2 | CES1 2698/4885SRC 2788/4885NR4A2 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.